NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Pharming Group initiates Phase II clinical trial evaluating leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes, including ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency, and PTEN deficiency, conducted at NIH.

GSK’s Arexvy showed sustained protection over three RSV seasons in adults 60+; 62.9% efficacy against RSV-related lower respiratory tract disease and 67.4% against severe RSV-LRTD after one dose. Mild-to-moderate adverse events were common, and revaccination may be needed.

John I. Gallin, M.D., former NIH Clinical Center director, passed away at 81. He led the center for 23 years, developed its research portfolio, and established key initiatives. Gallin was passionate about training clinical researchers and left a lasting legacy.

Pharming Group initiates Phase II clinical trial evaluating leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes, including ALPS-FAS, CTLA4 haploinsufficiency, NFKB1 haploinsufficiency, and PTEN deficiency, conducted at NIH.

A qualitative study with 60 allergists revealed enthusiasm for biologics' potential in treating food allergies, but concerns about novelty, cost, and overuse. Themes included perceived benefits, ideal uses, concerns, and biologics as the future of treatment. Omalizumab's FDA approval has arrived, but allergists' perceptions of biologics' risks and benefits remain largely unknown.

FDA grants Fast Track designation to Wockhardt's once-a-day antibiotic WCK 6777 for cUTI and cIAI. WCK 6777, active against meropenem-resistant Gram negative pathogens, completed a Phase I study with a promising safety profile.

Emergex's T cell-priming vaccine candidate against Betacoronaviruses selected by NIH/NIAID for Project NextGen, showing potential to address current and future coronavirus challenges.